• ftr-facebook
  • ftr-instagram
  • ftr-instagram
search-icon-img

Amanta Healthcare IPO Day 1: GMP, Subscription, Price Band and Expert Review

Amanta Healthcare IPO opened for subscription today with a price band of ₹120–₹126 per share. Backed by strong demand in the grey market and expert reviews, investors are keenly watching whether it’s worth applying.
featured-img
Amanta Healthcare IPO 2025

Amanta Healthcare IPO Day 1: Amanta Healthcare Limited’s much-awaited IPO opened for subscription today and will close on 3 September 2025. The pharma company has fixed its price band at Rs.120–Rs.126 per share, targeting to raise Rs.126 crore through a fresh issue of equity shares. The IPO will be listed on both BSE and NSE, with proceeds going directly into the company’s balance sheet.

Also Read: No punishment, no fine for keeping black money! Government changed the law for this reason

Grey Market Premium

As of today, Amanta Healthcare IPO GMP is Rs.26, according to market observers. This suggests the potential listing price could be around 20% higher than the upper band, reflecting positive sentiment among grey market traders.

Subscription Window

Bidding opened today at 10:00 AM and will remain active until 5:00 PM on all working days during the subscription period. Retail and institutional investors can place bids in this time frame until the issue closes on Wednesday, 3 September 2025.

IPO Key Details

  • GMP Today: Rs.26 premium in the grey market
  • Price Band: Rs.120–Rs.126 per share
  • Issue Size: Rs.126 crore via fresh issue
  • Lot Size: 1 lot = 119 shares
  • Allotment Date: 4 September 2025 (tentative)
  • Registrar: MUFG Intime India Private Limited
  • Lead Manager: Beeline Capital Advisors Private Limited
  • Listing Date: 8 September 2025 (tentative)

Expert Review

Analysts hold a mixed but positive stance on the IPO.

  • Minerva Capital Research has rated it as “May Subscribe”, citing strengths like an experienced promoter base, a wide distributor network, and expansion plans. However, risks such as a high debt-equity ratio and volatile raw material costs remain.
  • Exencial Research Partners has given it a “Buy” tag, highlighting the company’s strong foothold in sterile injectables and IV fluids, along with its domestic and export growth visibility. They advise cautious investors to wait, while long-term players can consider subscribing for potential wealth creation.

Also Read: Keep your money ready to earn! Tata Group's biggest IPO is coming on this day

.

tlbr_img1 Home tlbr_img2 Shorts tlbr_img3 Video tlbr_img4 Webstories